RVL Pharmaceuticals plc (RVLPQ)

Market Cap	111.00 -100.0%
Revenue (ttm)	36.92M +5.6%
Net Income	-68.27M
EPS	-0.70
Shares Out	111.41M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	8,781
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	42.50
RSI	48.35
Earnings Date	May 21, 2026

About RVL Pharmaceuticals

RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name t...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Brian Markison
• Country: United States
• Stock Exchange: OTCMKTS
• Ticker Symbol: RVLPQ